| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | histone H3K27 trimethyltransferase activity | 2.57e-06 | 3 | 19 | 2 | GO:0140951 | |
| GeneOntologyMolecularFunction | histone H3K27 methyltransferase activity | 1.28e-05 | 6 | 19 | 2 | GO:0046976 | |
| GeneOntologyMolecularFunction | transcription factor binding | 5.02e-05 | 753 | 19 | 6 | GO:0008134 | |
| GeneOntologyMolecularFunction | lncRNA binding | 5.01e-04 | 35 | 19 | 2 | GO:0106222 | |
| GeneOntologyMolecularFunction | histone H3 methyltransferase activity | 7.92e-04 | 44 | 19 | 2 | GO:0140938 | |
| GeneOntologyMolecularFunction | methyltransferase activity | 1.02e-03 | 213 | 19 | 3 | GO:0008168 | |
| GeneOntologyMolecularFunction | transferase activity, transferring one-carbon groups | 1.18e-03 | 224 | 19 | 3 | GO:0016741 | |
| GeneOntologyMolecularFunction | molecular adaptor activity | 1.22e-03 | 1356 | 19 | 6 | GO:0060090 | |
| GeneOntologyMolecularFunction | core promoter sequence-specific DNA binding | 1.24e-03 | 55 | 19 | 2 | GO:0001046 | |
| GeneOntologyMolecularFunction | histone modifying activity | 1.26e-03 | 229 | 19 | 3 | GO:0140993 | |
| GeneOntologyMolecularFunction | protein-lysine N-methyltransferase activity | 1.88e-03 | 68 | 19 | 2 | GO:0016279 | |
| GeneOntologyMolecularFunction | lysine N-methyltransferase activity | 1.94e-03 | 69 | 19 | 2 | GO:0016278 | |
| GeneOntologyMolecularFunction | DNA-binding transcription factor binding | 1.95e-03 | 582 | 19 | 4 | GO:0140297 | |
| GeneOntologyMolecularFunction | histone methyltransferase activity | 2.05e-03 | 71 | 19 | 2 | GO:0042054 | |
| GeneOntologyMolecularFunction | promoter-specific chromatin binding | 2.79e-03 | 83 | 19 | 2 | GO:1990841 | |
| GeneOntologyMolecularFunction | cargo receptor activity | 2.92e-03 | 85 | 19 | 2 | GO:0038024 | |
| GeneOntologyMolecularFunction | protein-macromolecule adaptor activity | 3.85e-03 | 1160 | 19 | 5 | GO:0030674 | |
| GeneOntologyMolecularFunction | protein methyltransferase activity | 4.26e-03 | 103 | 19 | 2 | GO:0008276 | |
| GeneOntologyMolecularFunction | N-methyltransferase activity | 4.42e-03 | 105 | 19 | 2 | GO:0008170 | |
| GeneOntologyMolecularFunction | RNA polymerase II-specific DNA-binding transcription factor binding | 6.83e-03 | 417 | 19 | 3 | GO:0061629 | |
| GeneOntologyMolecularFunction | chromatin DNA binding | 1.08e-02 | 167 | 19 | 2 | GO:0031490 | |
| GeneOntologyMolecularFunction | S-adenosylmethionine-dependent methyltransferase activity | 1.15e-02 | 172 | 19 | 2 | GO:0008757 | |
| GeneOntologyBiologicalProcess | regulation of transcription elongation by RNA polymerase II | 8.16e-05 | 93 | 19 | 3 | GO:0034243 | |
| GeneOntologyBiologicalProcess | chromatin organization | 1.10e-04 | 896 | 19 | 6 | GO:0006325 | |
| GeneOntologyBiologicalProcess | regulation of DNA-templated transcription elongation | 1.17e-04 | 105 | 19 | 3 | GO:0032784 | |
| GeneOntologyBiologicalProcess | negative regulation of transcription elongation by RNA polymerase II | 1.51e-04 | 20 | 19 | 2 | GO:0034244 | |
| GeneOntologyBiologicalProcess | protein-DNA complex organization | 2.00e-04 | 999 | 19 | 6 | GO:0071824 | |
| GeneOntologyBiologicalProcess | V(D)J recombination | 2.01e-04 | 23 | 19 | 2 | GO:0033151 | |
| GeneOntologyBiologicalProcess | negative regulation of DNA-templated transcription, elongation | 2.01e-04 | 23 | 19 | 2 | GO:0032785 | |
| GeneOntologyBiologicalProcess | transcription elongation by RNA polymerase II | 2.06e-04 | 127 | 19 | 3 | GO:0006368 | |
| GeneOntologyBiologicalProcess | DNA-templated transcription elongation | 2.98e-04 | 144 | 19 | 3 | GO:0006354 | |
| GeneOntologyBiologicalProcess | myelin assembly | 3.00e-04 | 28 | 19 | 2 | GO:0032288 | |
| GeneOntologyBiologicalProcess | negative regulation of stem cell differentiation | 4.17e-04 | 33 | 19 | 2 | GO:2000737 | |
| GeneOntologyBiologicalProcess | heterochromatin formation | 4.28e-04 | 163 | 19 | 3 | GO:0031507 | |
| GeneOntologyBiologicalProcess | chromatin remodeling | 4.51e-04 | 741 | 19 | 5 | GO:0006338 | |
| GeneOntologyBiologicalProcess | DNA methylation-dependent constitutive heterochromatin formation | 7.43e-04 | 44 | 19 | 2 | GO:0006346 | |
| GeneOntologyBiologicalProcess | negative regulation of gene expression, epigenetic | 8.10e-04 | 203 | 19 | 3 | GO:0045814 | |
| GeneOntologyBiologicalProcess | myelination | 8.45e-04 | 206 | 19 | 3 | GO:0042552 | |
| GeneOntologyBiologicalProcess | ensheathment of neurons | 8.82e-04 | 209 | 19 | 3 | GO:0007272 | |
| GeneOntologyBiologicalProcess | axon ensheathment | 8.82e-04 | 209 | 19 | 3 | GO:0008366 | |
| GeneOntologyBiologicalProcess | RNA localization | 9.83e-04 | 217 | 19 | 3 | GO:0006403 | |
| GeneOntologyBiologicalProcess | Schwann cell differentiation | 1.16e-03 | 55 | 19 | 2 | GO:0014037 | |
| GeneOntologyBiologicalProcess | facultative heterochromatin formation | 1.16e-03 | 55 | 19 | 2 | GO:0140718 | |
| GeneOntologyBiologicalProcess | negative regulation of DNA-templated transcription | 1.21e-03 | 1399 | 19 | 6 | GO:0045892 | |
| GeneOntologyBiologicalProcess | methylation | 1.22e-03 | 234 | 19 | 3 | GO:0032259 | |
| GeneOntologyBiologicalProcess | negative regulation of RNA biosynthetic process | 1.28e-03 | 1413 | 19 | 6 | GO:1902679 | |
| GeneOntologyCellularComponent | chromatin silencing complex | 7.08e-05 | 14 | 19 | 2 | GO:0005677 | |
| Domain | SET | 7.04e-04 | 41 | 18 | 2 | PF00856 | |
| Domain | SET | 8.85e-04 | 46 | 18 | 2 | SM00317 | |
| Domain | SET_dom | 1.05e-03 | 50 | 18 | 2 | IPR001214 | |
| Domain | SET | 1.05e-03 | 50 | 18 | 2 | PS50280 | |
| Domain | PHD | 2.34e-03 | 75 | 18 | 2 | PF00628 | |
| Domain | Znf_PHD-finger | 2.59e-03 | 79 | 18 | 2 | IPR019787 | |
| Domain | EGF_CA | 3.06e-03 | 86 | 18 | 2 | PF07645 | |
| Domain | PHD | 3.27e-03 | 89 | 18 | 2 | SM00249 | |
| Domain | Znf_PHD | 3.41e-03 | 91 | 18 | 2 | IPR001965 | |
| Domain | ZF_PHD_2 | 3.71e-03 | 95 | 18 | 2 | PS50016 | |
| Domain | ZF_PHD_1 | 3.79e-03 | 96 | 18 | 2 | PS01359 | |
| Domain | EGF_CA | 6.05e-03 | 122 | 18 | 2 | SM00179 | |
| Domain | EGF-like_Ca-bd_dom | 6.24e-03 | 124 | 18 | 2 | IPR001881 | |
| Domain | EGF | 6.44e-03 | 126 | 18 | 2 | PF00008 | |
| Domain | - | 8.61e-03 | 449 | 18 | 3 | 3.30.40.10 | |
| Domain | Znf_FYVE_PHD | 8.67e-03 | 147 | 18 | 2 | IPR011011 | |
| Domain | Znf_RING/FYVE/PHD | 9.14e-03 | 459 | 18 | 3 | IPR013083 | |
| Pubmed | ZMYM3 regulates BRCA1 localization at damaged chromatin to promote DNA repair. | 1.55e-08 | 150 | 19 | 5 | 28242625 | |
| Pubmed | 2.83e-07 | 2 | 19 | 2 | 37069142 | ||
| Pubmed | The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. | 2.04e-06 | 1203 | 19 | 7 | 29180619 | |
| Pubmed | 2.82e-06 | 5 | 19 | 2 | 23063525 | ||
| Pubmed | The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase. | 5.60e-06 | 220 | 19 | 4 | 34091597 | |
| Pubmed | A systems-wide screen identifies substrates of the SCFβTrCP ubiquitin ligase. | 6.91e-06 | 232 | 19 | 4 | 25515538 | |
| Pubmed | 8.62e-06 | 1497 | 19 | 7 | 31527615 | ||
| Pubmed | 9.43e-06 | 251 | 19 | 4 | 28077445 | ||
| Pubmed | 2.64e-05 | 1168 | 19 | 6 | 19946888 | ||
| Pubmed | 3.81e-05 | 1247 | 19 | 6 | 27684187 | ||
| Pubmed | Substrate trapping proteomics reveals targets of the βTrCP2/FBXW11 ubiquitin ligase. | 4.52e-05 | 128 | 19 | 3 | 25332235 | |
| Pubmed | Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. | 6.01e-05 | 1353 | 19 | 6 | 29467282 | |
| Pubmed | Assembly of the U5 snRNP component PRPF8 is controlled by the HSP90/R2TP chaperones. | 7.71e-05 | 1415 | 19 | 6 | 28515276 | |
| Pubmed | Xrcc4 physically links DNA end processing by polynucleotide kinase to DNA ligation by DNA ligase IV. | 8.42e-05 | 25 | 19 | 2 | 15385968 | |
| Pubmed | TNIP2 is a Hub Protein in the NF-κB Network with Both Protein and RNA Mediated Interactions. | 1.11e-04 | 922 | 19 | 5 | 27609421 | |
| Pubmed | 1.14e-04 | 29 | 19 | 2 | 24105743 | ||
| Pubmed | N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective. | 1.17e-04 | 934 | 19 | 5 | 33916271 | |
| Pubmed | Autophagy negatively regulates cancer cell proliferation via selectively targeting VPRBP. | 1.22e-04 | 30 | 19 | 2 | 22963397 | |
| Pubmed | BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs. | 1.30e-04 | 31 | 19 | 2 | 23086144 | |
| Pubmed | Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase. | 1.66e-04 | 35 | 19 | 2 | 19287380 | |
| Pubmed | 1.76e-04 | 36 | 19 | 2 | 17289661 | ||
| Pubmed | 1.76e-04 | 36 | 19 | 2 | 22421546 | ||
| Pubmed | Cellular RNA binding proteins NS1-BP and hnRNP K regulate influenza A virus RNA splicing. | 2.18e-04 | 40 | 19 | 2 | 23825951 | |
| Pubmed | Direct interaction between hnRNP-M and CDC5L/PLRG1 proteins affects alternative splice site choice. | 2.46e-04 | 582 | 19 | 4 | 20467437 | |
| Pubmed | 2.52e-04 | 43 | 19 | 2 | 30026490 | ||
| Pubmed | 2.76e-04 | 236 | 19 | 3 | 36339263 | ||
| Pubmed | 2.76e-04 | 45 | 19 | 2 | 30619335 | ||
| Pubmed | The in vivo Interaction Landscape of Histones H3.1 and H3.3. | 2.91e-04 | 608 | 19 | 4 | 36089195 | |
| Pubmed | 3.04e-04 | 244 | 19 | 3 | 30349055 | ||
| Pubmed | 3.41e-04 | 634 | 19 | 4 | 34591612 | ||
| Pubmed | ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1. | 3.78e-04 | 1201 | 19 | 5 | 35696571 | |
| Pubmed | Proteomic and functional analysis of Argonaute-containing mRNA-protein complexes in human cells. | 4.43e-04 | 57 | 19 | 2 | 17932509 | |
| Pubmed | 4.59e-04 | 686 | 19 | 4 | 28380382 | ||
| Pubmed | Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma. | 4.66e-04 | 1257 | 19 | 5 | 36526897 | |
| Pubmed | H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. | 5.32e-04 | 1294 | 19 | 5 | 30804502 | |
| Interaction | RAN interactions | 3.47e-06 | 475 | 19 | 6 | int:RAN | |
| Interaction | KPNB1 interactions | 7.57e-06 | 544 | 19 | 6 | int:KPNB1 | |
| Interaction | TERF2IP interactions | 8.23e-06 | 552 | 19 | 6 | int:TERF2IP | |
| Interaction | CUL1 interactions | 9.11e-06 | 876 | 19 | 7 | int:CUL1 | |
| Interaction | NUP50 interactions | 1.29e-05 | 341 | 19 | 5 | int:NUP50 | |
| Interaction | DHX9 interactions | 2.31e-05 | 662 | 19 | 6 | int:DHX9 | |
| Interaction | KIF20A interactions | 3.00e-05 | 1052 | 19 | 7 | int:KIF20A | |
| Interaction | HDAC1 interactions | 4.18e-05 | 1108 | 19 | 7 | int:HDAC1 | |
| Interaction | SNW1 interactions | 4.56e-05 | 747 | 19 | 6 | int:SNW1 | |
| Interaction | H3-4 interactions | 4.77e-05 | 448 | 19 | 5 | int:H3-4 | |
| Interaction | MACROH2A1 interactions | 5.30e-05 | 458 | 19 | 5 | int:MACROH2A1 | |
| Interaction | PIN4 interactions | 5.79e-05 | 81 | 19 | 3 | int:PIN4 | |
| Interaction | NCL interactions | 6.59e-05 | 798 | 19 | 6 | int:NCL | |
| Interaction | SEPTIN6 interactions | 7.41e-05 | 88 | 19 | 3 | int:SEPTIN6 | |
| Interaction | KPNA3 interactions | 7.50e-05 | 248 | 19 | 4 | int:KPNA3 | |
| Interaction | H1-1 interactions | 8.58e-05 | 507 | 19 | 5 | int:H1-1 | |
| Interaction | YWHAE interactions | 9.31e-05 | 1256 | 19 | 7 | int:YWHAE | |
| Interaction | KPNA2 interactions | 9.58e-05 | 519 | 19 | 5 | int:KPNA2 | |
| Interaction | CKB interactions | 1.04e-04 | 270 | 19 | 4 | int:CKB | |
| Interaction | LMNA interactions | 1.08e-04 | 1286 | 19 | 7 | int:LMNA | |
| Interaction | RBX1 interactions | 1.35e-04 | 558 | 19 | 5 | int:RBX1 | |
| Interaction | PCDHB1 interactions | 1.43e-04 | 19 | 19 | 2 | int:PCDHB1 | |
| Interaction | CUL5 interactions | 1.45e-04 | 567 | 19 | 5 | int:CUL5 | |
| Interaction | HYDIN interactions | 1.75e-04 | 21 | 19 | 2 | int:HYDIN | |
| Interaction | SUMO2 interactions | 1.76e-04 | 591 | 19 | 5 | int:SUMO2 | |
| Interaction | HSPA6 interactions | 1.80e-04 | 311 | 19 | 4 | int:HSPA6 | |
| Interaction | RNF4 interactions | 1.94e-04 | 1412 | 19 | 7 | int:RNF4 | |
| Interaction | HNRNPF interactions | 2.00e-04 | 607 | 19 | 5 | int:HNRNPF | |
| Interaction | LMNB1 interactions | 2.04e-04 | 610 | 19 | 5 | int:LMNB1 | |
| Interaction | ITGB4 interactions | 2.10e-04 | 125 | 19 | 3 | int:ITGB4 | |
| Interaction | RCHY1 interactions | 2.13e-04 | 325 | 19 | 4 | int:RCHY1 | |
| Interaction | VAT1 interactions | 2.20e-04 | 127 | 19 | 3 | int:VAT1 | |
| Interaction | PTPN1 interactions | 2.29e-04 | 625 | 19 | 5 | int:PTPN1 | |
| Interaction | CTNNB1 interactions | 2.40e-04 | 1009 | 19 | 6 | int:CTNNB1 | |
| Interaction | ATP5F1A interactions | 2.55e-04 | 640 | 19 | 5 | int:ATP5F1A | |
| Interaction | ANP32A interactions | 2.58e-04 | 134 | 19 | 3 | int:ANP32A | |
| Interaction | TRIM55 interactions | 2.67e-04 | 345 | 19 | 4 | int:TRIM55 | |
| Interaction | HSP90B1 interactions | 2.74e-04 | 650 | 19 | 5 | int:HSP90B1 | |
| Interaction | GCN1 interactions | 2.79e-04 | 349 | 19 | 4 | int:GCN1 | |
| Interaction | KPNA1 interactions | 2.85e-04 | 351 | 19 | 4 | int:KPNA1 | |
| Interaction | PYHIN1 interactions | 3.07e-04 | 358 | 19 | 4 | int:PYHIN1 | |
| Interaction | SRP14 interactions | 3.34e-04 | 366 | 19 | 4 | int:SRP14 | |
| Interaction | MAP10 interactions | 3.37e-04 | 29 | 19 | 2 | int:MAP10 | |
| Interaction | BOD1L1 interactions | 3.52e-04 | 149 | 19 | 3 | int:BOD1L1 | |
| Interaction | RPL13 interactions | 3.86e-04 | 700 | 19 | 5 | int:RPL13 | |
| Interaction | RB1CC1 interactions | 4.13e-04 | 387 | 19 | 4 | int:RB1CC1 | |
| Interaction | SYNCRIP interactions | 4.42e-04 | 721 | 19 | 5 | int:SYNCRIP | |
| Interaction | HSPA9 interactions | 4.60e-04 | 727 | 19 | 5 | int:HSPA9 | |
| Interaction | CUL4B interactions | 4.63e-04 | 728 | 19 | 5 | int:CUL4B | |
| Interaction | HDAC4 interactions | 5.11e-04 | 744 | 19 | 5 | int:HDAC4 | |
| Interaction | H3-3A interactions | 5.27e-04 | 749 | 19 | 5 | int:H3-3A | |
| Interaction | SMARCA5 interactions | 5.37e-04 | 415 | 19 | 4 | int:SMARCA5 | |
| Interaction | ALYREF interactions | 5.42e-04 | 416 | 19 | 4 | int:ALYREF | |
| Interaction | MYH9 interactions | 5.43e-04 | 754 | 19 | 5 | int:MYH9 | |
| Interaction | DYRK2 interactions | 5.44e-04 | 173 | 19 | 3 | int:DYRK2 | |
| Interaction | DDX17 interactions | 5.93e-04 | 426 | 19 | 4 | int:DDX17 | |
| Interaction | SRP9 interactions | 5.98e-04 | 427 | 19 | 4 | int:SRP9 | |
| Interaction | GPC1 interactions | 6.01e-04 | 179 | 19 | 3 | int:GPC1 | |
| Interaction | RORA interactions | 6.11e-04 | 39 | 19 | 2 | int:RORA | |
| Interaction | AGO1 interactions | 6.41e-04 | 183 | 19 | 3 | int:AGO1 | |
| Interaction | NSFL1C interactions | 7.37e-04 | 192 | 19 | 3 | int:NSFL1C | |
| Interaction | PABPN1 interactions | 7.37e-04 | 192 | 19 | 3 | int:PABPN1 | |
| Interaction | STMN1 interactions | 7.71e-04 | 195 | 19 | 3 | int:STMN1 | |
| Interaction | C2CD4B interactions | 7.78e-04 | 44 | 19 | 2 | int:C2CD4B | |
| Interaction | RPL27A interactions | 7.84e-04 | 459 | 19 | 4 | int:RPL27A | |
| Interaction | RCC1 interactions | 8.42e-04 | 201 | 19 | 3 | int:RCC1 | |
| Interaction | PRMT5 interactions | 8.64e-04 | 471 | 19 | 4 | int:PRMT5 | |
| Interaction | FBXW11 interactions | 8.78e-04 | 473 | 19 | 4 | int:FBXW11 | |
| Interaction | RGPD3 interactions | 8.88e-04 | 47 | 19 | 2 | int:RGPD3 | |
| Interaction | ABCF2 interactions | 9.42e-04 | 209 | 19 | 3 | int:ABCF2 | |
| Interaction | RANBP1 interactions | 9.69e-04 | 211 | 19 | 3 | int:RANBP1 | |
| Interaction | H3C3 interactions | 1.04e-03 | 495 | 19 | 4 | int:H3C3 | |
| Interaction | RPS6KL1 interactions | 1.04e-03 | 51 | 19 | 2 | int:RPS6KL1 | |
| Interaction | RPS6 interactions | 1.06e-03 | 874 | 19 | 5 | int:RPS6 | |
| Interaction | DHX15 interactions | 1.10e-03 | 502 | 19 | 4 | int:DHX15 | |
| Interaction | KPNA4 interactions | 1.17e-03 | 225 | 19 | 3 | int:KPNA4 | |
| Interaction | ILF3 interactions | 1.19e-03 | 896 | 19 | 5 | int:ILF3 | |
| Interaction | RPS20 interactions | 1.19e-03 | 513 | 19 | 4 | int:RPS20 | |
| Interaction | RPS9 interactions | 1.20e-03 | 515 | 19 | 4 | int:RPS9 | |
| Interaction | FBXO34 interactions | 1.21e-03 | 55 | 19 | 2 | int:FBXO34 | |
| Interaction | H3C1 interactions | 1.22e-03 | 901 | 19 | 5 | int:H3C1 | |
| Interaction | ARMC12 interactions | 1.26e-03 | 56 | 19 | 2 | int:ARMC12 | |
| Interaction | S100A6 interactions | 1.29e-03 | 233 | 19 | 3 | int:S100A6 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr2q37 | 3.90e-03 | 226 | 19 | 2 | chr2q37 | |
| GeneFamily | Zinc fingers C2H2-type|Lysine methyltransferases|PR/SET domain family | 1.87e-04 | 34 | 11 | 2 | 487 | |
| GeneFamily | PHD finger proteins | 1.31e-03 | 90 | 11 | 2 | 88 | |
| Coexpression | GOLDRATH_IMMUNE_MEMORY | 1.44e-05 | 66 | 19 | 3 | M10845 | |
| Coexpression | GOLDRATH_IMMUNE_MEMORY | 1.64e-05 | 69 | 19 | 3 | MM621 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN | 1.66e-05 | 467 | 19 | 5 | M1347 | |
| Coexpression | SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_DN | 1.97e-05 | 484 | 19 | 5 | MM999 | |
| Coexpression | GRUETZMANN_PANCREATIC_CANCER_UP | 1.14e-04 | 359 | 19 | 4 | M15193 | |
| Coexpression | GAZIN_EPIGENETIC_SILENCING_BY_KRAS | 1.48e-04 | 25 | 19 | 2 | M1770 | |
| Coexpression | WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK | 1.57e-04 | 147 | 19 | 3 | MM1316 | |
| Coexpression | WAKABAYASHI_ADIPOGENESIS_PPARG_RXRA_BOUND_WITH_H4K20ME1_MARK | 1.60e-04 | 148 | 19 | 3 | M2420 | |
| Coexpression | GAZIN_EPIGENETIC_SILENCING_BY_KRAS | 1.73e-04 | 27 | 19 | 2 | MM744 | |
| Coexpression | GSE6090_UNSTIM_VS_DC_SIGN_STIM_DC_UP | 2.24e-04 | 166 | 19 | 3 | M6811 | |
| Coexpression | GSE21033_3H_VS_24H_POLYIC_STIM_DC_UP | 2.24e-04 | 166 | 19 | 3 | M7722 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_UP | 2.36e-04 | 434 | 19 | 4 | M15150 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_UP | 2.66e-04 | 448 | 19 | 4 | MM1044 | |
| Coexpression | GSE11973_MIR223_KOVS_WT_BONE_MARROW_NEUTROPHIL_DN | 2.71e-04 | 177 | 19 | 3 | M394 | |
| Coexpression | CUI_DEVELOPING_HEART_TRABECULAR_ATRIAL_CARDIOMYOCYTE | 2.80e-04 | 179 | 19 | 3 | M39308 | |
| Coexpression | GSE27291_0H_VS_7D_STIM_GAMMADELTA_TCELL_UP | 3.23e-04 | 188 | 19 | 3 | M8452 | |
| Coexpression | VERRECCHIA_DELAYED_RESPONSE_TO_TGFB1 | 3.27e-04 | 37 | 19 | 2 | M16643 | |
| Coexpression | DODD_NASOPHARYNGEAL_CARCINOMA_UP | 3.51e-04 | 1407 | 19 | 6 | M14427 | |
| Coexpression | BROWNE_HCMV_INFECTION_48HR_DN | 3.52e-04 | 482 | 19 | 4 | M12144 | |
| Coexpression | GSE4748_LPS_VS_LPS_AND_CYANOBACTERIUM_LPSLIKE_STIM_DC_3H_UP | 3.54e-04 | 194 | 19 | 3 | M6493 | |
| Coexpression | PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP | 3.60e-04 | 195 | 19 | 3 | M13736 | |
| Coexpression | GSE45739_NRAS_KO_VS_WT_UNSTIM_CD4_TCELL_DN | 3.71e-04 | 197 | 19 | 3 | M9879 | |
| Coexpression | GSE37416_0H_VS_3H_F_TULARENSIS_LVS_NEUTROPHIL_DN | 3.71e-04 | 197 | 19 | 3 | M5342 | |
| Coexpression | GSE2770_TGFB_AND_IL4_VS_IL4_TREATED_ACT_CD4_TCELL_6H_DN | 3.76e-04 | 198 | 19 | 3 | M6104 | |
| Coexpression | GSE33424_CD161_HIGH_VS_NEG_CD8_TCELL_DN | 3.82e-04 | 199 | 19 | 3 | M8542 | |
| Coexpression | GSE2585_THYMIC_DC_VS_MTEC_UP | 3.82e-04 | 199 | 19 | 3 | M6289 | |
| Coexpression | GSE17721_LPS_VS_PAM3CSK4_6H_BMDC_DN | 3.82e-04 | 199 | 19 | 3 | M3919 | |
| Coexpression | GSE6674_ANTI_IGM_VS_PL2_3_STIM_BCELL_DN | 3.82e-04 | 199 | 19 | 3 | M6932 | |
| Coexpression | GSE2585_THYMIC_DC_VS_MTEC_DN | 3.88e-04 | 200 | 19 | 3 | M6283 | |
| Coexpression | GSE12845_IGD_POS_BLOOD_VS_PRE_GC_TONSIL_BCELL_DN | 3.88e-04 | 200 | 19 | 3 | M3188 | |
| Coexpression | GSE17721_POLYIC_VS_GARDIQUIMOD_8H_BMDC_DN | 3.88e-04 | 200 | 19 | 3 | M4027 | |
| Coexpression | GSE2770_UNTREATED_VS_IL12_TREATED_ACT_CD4_TCELL_6H_UP | 3.88e-04 | 200 | 19 | 3 | M6092 | |
| Coexpression | GOLDRATH_NAIVE_VS_MEMORY_CD8_TCELL_DN | 3.88e-04 | 200 | 19 | 3 | M3039 | |
| Coexpression | CHICAS_RB1_TARGETS_SENESCENT | 6.40e-04 | 565 | 19 | 4 | M2125 | |
| Coexpression | HEVNER_CORTEX_APICAL_AND_BASAL_INTERMEDIATE_PROGENITOR_CELLS | 7.23e-04 | 55 | 19 | 2 | MM397 | |
| Coexpression | YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_2 | 8.03e-04 | 58 | 19 | 2 | M2021 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Flanking Eminence_top-relative-expression-ranked_2500_k-means-cluster#5 | 6.18e-05 | 831 | 19 | 6 | Facebase_RNAseq_e10.5_Neural Epithelium Flanking Eminence_2500_K5 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Mandibular Arch_top-relative-expression-ranked_1000_k-means-cluster#3 | 8.65e-05 | 271 | 19 | 4 | Facebase_RNAseq_e10.5_Mandibular Arch_1000_K3 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_top-relative-expression-ranked_2500_k-means-cluster#1 | 1.85e-04 | 629 | 19 | 5 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Medial Eminence_2500_K1 | |
| ToppCell | 367C-Lymphocytic-ILC-ILC-1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 4.74e-05 | 168 | 19 | 3 | 80233a13135fd159f5764336a1fe67fba237776b | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature|Brain_organoid / Sample Type, Dataset, Time_group, and Cell type. | 6.31e-05 | 185 | 19 | 3 | 857c7ca8493e91ef1d0078ddafd6082020f9b169 | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Myeloid-Dendritic|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.42e-05 | 186 | 19 | 3 | 38f9f7d3b782978fd23b2a7fe565266285d39e44 | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Myeloid-Dendritic-conventional_dendritic_cell|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.62e-05 | 188 | 19 | 3 | e35104ca327c2d9eb6ffed658051f62f855a0a0e | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Myeloid-Dendritic-conventional_dendritic_cell-DC_c2-CD1C|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 6.94e-05 | 191 | 19 | 3 | 5c0c44612b4cdbf89c0f1f219416374a7541f610 | |
| ToppCell | droplet-Thymus-nan-3m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.05e-05 | 192 | 19 | 3 | d9e61b2722aa81e4f6e11865a04f2f1e75b794ab | |
| ToppCell | 3'_v3-blood-Lymphocytic_NK-NK_CD56bright_CD16-|blood / Manually curated celltypes from each tissue | 7.38e-05 | 195 | 19 | 3 | 1470f562ebcfe7da367964ecfd6c7f43bcdb4a73 | |
| ToppCell | droplet-Thymus-nan-21m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.38e-05 | 195 | 19 | 3 | 2416efe0b10ef28d0107808d1347bc34f87f92b7 | |
| ToppCell | droplet-Tongue-nan-3m-Epithelial-suprabasal_differentiating|Tongue / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.49e-05 | 196 | 19 | 3 | 27364b577d77aefaa147abb346c46fce61e28ec3 | |
| ToppCell | droplet-Thymus-nan-21m|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.49e-05 | 196 | 19 | 3 | 313d66313d7c93d9ae4c8b790262ba7a85b34fe4 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-Prolif_T-F|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.61e-05 | 197 | 19 | 3 | 04aaf35ef4db6325b2b2b92e93272f1973764b78 | |
| ToppCell | P03-Mesenchymal-myocytic_cell|P03 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 7.61e-05 | 197 | 19 | 3 | 079db904a08743b3c555cb7b3f5fb5c978dde25a | |
| ToppCell | TCGA-Skin-Metastatic-Melanoma-Skin_Cutaneous_Melanoma|TCGA-Skin / Sample_Type by Project: Shred V9 | 7.72e-05 | 198 | 19 | 3 | 62cbf4b29e8af4983fb47a17f96da62682a5137e | |
| ToppCell | TCGA-Skin-Metastatic-Melanoma|TCGA-Skin / Sample_Type by Project: Shred V9 | 7.72e-05 | 198 | 19 | 3 | af4fb9eb2295c7b90624b38ba25619aa15254efa | |
| ToppCell | PND10-Mesenchymal-Mesenchymal_myocytic|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 7.72e-05 | 198 | 19 | 3 | a699b365d3b6149f13f02b2e2ae9b6fdce761848 | |
| ToppCell | TCGA-Skin-Metastatic|TCGA-Skin / Sample_Type by Project: Shred V9 | 7.72e-05 | 198 | 19 | 3 | ad39cce004867f083f8da1954e0cf5a263815184 | |
| ToppCell | 3'-Adult-Appendix-Epithelial-epithelial_progenitor_cell-TA|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.84e-05 | 199 | 19 | 3 | d1a3eaef9e84d0572776e8468099d669b8a98ef7 | |
| ToppCell | 3'-Adult-Appendix-Epithelial-epithelial_progenitor_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.84e-05 | 199 | 19 | 3 | 7ff034b384f8fa4e027025aa5bf8cb856d793b18 | |
| ToppCell | 3'-Adult-Appendix-Epithelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.84e-05 | 199 | 19 | 3 | 77bdd3df106c05acc173555ce13243d93c50e94d | |
| ToppCell | wk_08-11-Mesenchymal-Myofibro_&_SMC-Early_airway_SMC_2|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 7.84e-05 | 199 | 19 | 3 | a207b4891881149d4c50721310690fd794157723 | |
| ToppCell | lymphoid-NK_cell-NK_cell|NK_cell / Lineage, cell class and subclass | 7.84e-05 | 199 | 19 | 3 | 945fbf5845403a8b22d04963f50ad69c414b6153 | |
| ToppCell | 3'-Adult-Appendix|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 7.84e-05 | 199 | 19 | 3 | 32ff62019535ea30059b63a2686c565baa54bfee | |
| ToppCell | 343B-Epithelial_cells-Epithelial-E_(AT2)-|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 1.89e-03 | 153 | 19 | 2 | 32cf4ca828d228f23366480305592f9813fed7ff | |
| ToppCell | 343B-Epithelial_cells-Epithelial-E_(AT2)|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 1.89e-03 | 153 | 19 | 2 | d5f5399ebbbff508c96ce7f01272716b61597ab5 | |
| ToppCell | IIH-Treg|IIH / Condition, Cell_class and T cell subcluster | 1.89e-03 | 153 | 19 | 2 | 17704e18833812fcf2a2727b1e3f8a9984ba5b59 | |
| ToppCell | IIH-Treg-CD4_Treg|IIH / Condition, Cell_class and T cell subcluster | 1.92e-03 | 154 | 19 | 2 | d2211a892654b92decb208969040920f7ae8ba1e | |
| ToppCell | facs-BAT-Fat-24m-Lymphocytic-NK_cell|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.94e-03 | 155 | 19 | 2 | 550e7e7e52829244ead829e5be010bfdc71e2ba5 | |
| ToppCell | TCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Oligoastrocytoma|TCGA-Brain / Sample_Type by Project: Shred V9 | 2.09e-03 | 161 | 19 | 2 | 347edb0de10850b7d16c40945751033289289c9b | |
| ToppCell | Adult-Mesenchymal-myofibroblast_cell-D175|Adult / Lineage, Cell type, age group and donor | 2.09e-03 | 161 | 19 | 2 | 048b7dc00746987a24bf870d4d278c4183eb04a2 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.09e-03 | 161 | 19 | 2 | a7e09cf2ca6cd70d40d08440fe9c5ab9befa1b79 | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Myocytic_interstitial_cell-Cycling_Myofibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.09e-03 | 161 | 19 | 2 | 08920a716f6ec62538e361211455a30ad726d7be | |
| ToppCell | facs-Spleen-nan-3m-Lymphocytic-NK_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.17e-03 | 164 | 19 | 2 | a187bd5beca017ef657ef07c006e7f94ea3b911b | |
| ToppCell | facs-BAT-Fat-18m-Lymphocytic-NK_cell|BAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.17e-03 | 164 | 19 | 2 | ab9c17f86b98e1a4d5db1bd3086edab1320ebda8 | |
| ToppCell | facs-Marrow-T_cells-18m-Lymphocytic-late_pro_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.19e-03 | 165 | 19 | 2 | 0edd56e8d14eaeced9882dd9206ea93e8f402e8d | |
| ToppCell | facs-Marrow-T_cells-18m-Lymphocytic-late_pro-B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.19e-03 | 165 | 19 | 2 | fa3aadfff6fb1e7f142db333c60c2cba02b17e6c | |
| ToppCell | TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-5|TCGA-Ovary / Sample_Type by Project: Shred V9 | 2.22e-03 | 166 | 19 | 2 | 32d2eaf8a5d03881bf74d680825af2d5110b082d | |
| ToppCell | droplet-Spleen-nan-21m-Lymphocytic-NK_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.25e-03 | 167 | 19 | 2 | 92ddabbe55315856d8ea6f8db1560b6d97636bac | |
| ToppCell | facs-Spleen-nan-3m-Lymphocytic-nan|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.27e-03 | 168 | 19 | 2 | 74dc46738f1d0a448df6c9b8288b515d92697792 | |
| ToppCell | PND10-Immune-Immune_Lymphocytic_T/NK-Lymphocytic_ILC-NK-ILC-ILC_prolif|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.30e-03 | 169 | 19 | 2 | 20fbf78382fb0ba9a63ab1aa0abc615476994ac5 | |
| ToppCell | facs-SCAT-Fat-18m-Lymphocytic-T_cell|SCAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.30e-03 | 169 | 19 | 2 | 700a3a36c379872585204caa6a6cc269b036ae22 | |
| ToppCell | ASK454-Immune-NK_cell|Immune / Donor, Lineage and Cell class of Lung cells from Dropseq | 2.33e-03 | 170 | 19 | 2 | 84705434234bf2fbb5256bd5a1f6ab54c01c5a51 | |
| ToppCell | 10x5'-Lung-Lymphocytic_T_CD4/8-lo-Cycling_T|Lung / Manually curated celltypes from each tissue | 2.35e-03 | 171 | 19 | 2 | 976361f67dd725870e0513ae7a92f2dcaee17148 | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8|lymph-node_spleen / Manually curated celltypes from each tissue | 2.35e-03 | 171 | 19 | 2 | 2e9a20f8980b78325c52065a9c14ab3656267c05 | |
| ToppCell | Lymphoid-Lymphoid-B_cells_(cycle)|Lymphoid / shred on cell class and cell subclass (v4) | 2.38e-03 | 172 | 19 | 2 | f39822afcc35f0fbf68b8ffd1894e4b6c8d7a80c | |
| ToppCell | ASK454-Immune-NK_cell|ASK454 / Donor, Lineage and Cell class of Lung cells from Dropseq | 2.38e-03 | 172 | 19 | 2 | c9e738c3540ee09b08805b1cdb66b4a0d9d40d33 | |
| ToppCell | 356C-Lymphocytic-CD4_T-cell-Treg_cell_1|356C / Donor, Lineage, Cell class and subclass (all cells) | 2.41e-03 | 173 | 19 | 2 | e3cb7c8c09f937da6b8d673e9adfec5d94a15548 | |
| ToppCell | PBMC-Severe-Myeloid-cDC-cDC-cDC_12|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 2.41e-03 | 173 | 19 | 2 | a55f310c533432e9e26e400026a5b47245152976 | |
| ToppCell | PBMC-Severe-Myeloid-cDC-cDC-cDC_12|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 2.41e-03 | 173 | 19 | 2 | 9c7386bf0a899882c733f0b4921a96afde032a7d | |
| ToppCell | kidney_cells-Adult_normal_reference-Epithelial-Intermediate_tubule_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.44e-03 | 174 | 19 | 2 | 583955b4db442ba0583e2312af242f050547f9d6 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-late_pro_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.44e-03 | 174 | 19 | 2 | c2fc78dd6c440737ded59676961e4c7b923084ce | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-late_pro-B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.44e-03 | 174 | 19 | 2 | 021ebc6ec022b992d7b25333ba0b7416371e041b | |
| ToppCell | facs-Heart-RV-18m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.46e-03 | 175 | 19 | 2 | d8e385320f554d974538b7cdc4f8e4767f1455f2 | |
| ToppCell | facs-Heart-RV-18m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.46e-03 | 175 | 19 | 2 | cf15465855602ba135752c18755e3e058dbd42ec | |
| ToppCell | facs-Skin-nan-24m-Epithelial-basal_cell_of_epidermis|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.46e-03 | 175 | 19 | 2 | 21542be95059983d2c8bdf01ec711fdbf1ec1f62 | |
| ToppCell | facs-Spleen-nan-18m-Lymphocytic-nan|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.49e-03 | 176 | 19 | 2 | a23d484aff5ad094333b2feae9106ca219514711 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.49e-03 | 176 | 19 | 2 | c6484334187f64cd00cd35e77d8ae436556b4260 | |
| ToppCell | 343B-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)-|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.49e-03 | 176 | 19 | 2 | 2e94bbe17c0bb65dc58b4ebc0cb829258bd7373b | |
| ToppCell | droplet-Heart-nan-3m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.49e-03 | 176 | 19 | 2 | 749b47eac5436fa34e0d243ffbc6f1897f4e431e | |
| ToppCell | 343B-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.49e-03 | 176 | 19 | 2 | f33ab41d121b59d871ad7d48ca021524a027d2ef | |
| ToppCell | droplet-Lung-18m-Hematologic-myeloid-classical_monocyte_proliferating-classical_monocyte_proliferating_l2|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.49e-03 | 176 | 19 | 2 | 1510cdfcfb46ce1196a1220c07fb5f3986c81b78 | |
| ToppCell | (1)_Control_(PBS)-(2)_LEPR+_perivascular_cells_and_VE-Cad+_vascular_cells_(mixed)|(1)_Control_(PBS) / Stress and Cell class | 2.52e-03 | 177 | 19 | 2 | d9e5ac5b8949a77e88e8094079167e4cf2c1bbd1 | |
| ToppCell | (01)_Cycling_Basal_(homeostasis)|World / shred by cell type and Timepoint | 2.52e-03 | 177 | 19 | 2 | 05c57578142a6662f18b294d5cc11e6efd6b0f8e | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_osteo-stroma-chondrocyte|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 2.52e-03 | 177 | 19 | 2 | 915b848d789051a1c3bc6f6dc86955bb752276ab | |
| ToppCell | facs-Heart-RA-18m|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.55e-03 | 178 | 19 | 2 | b505e2550860e777535ee95f29c936242fd607f1 | |
| ToppCell | COVID-19_Convalescent-Classical_Monocyte-cMono_4|Classical_Monocyte / Disease condition and Cell class | 2.57e-03 | 179 | 19 | 2 | 9d51318ac198a8801bd5c7031ebf2b0c74ffeeb6 | |
| ToppCell | COVID-19_Convalescent-Classical_Monocyte-cMono_4|COVID-19_Convalescent / Disease condition and Cell class | 2.57e-03 | 179 | 19 | 2 | 366e4a31db9e80fd1770ac9f1ae148fefeb9f7df | |
| ToppCell | 356C-Lymphocytic-ILC-ILC-1|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 2.60e-03 | 180 | 19 | 2 | cedbe692c5257fb6f9a552e2f197163626ac17d9 | |
| ToppCell | RA-11._Adipocyte|RA / Chamber and Cluster_Paper | 2.60e-03 | 180 | 19 | 2 | d48a3d27357f7d184132a6805950f93080146b59 | |
| ToppCell | 368C-Lymphocytic-ILC-ILC-2|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 2.60e-03 | 180 | 19 | 2 | eb5a57604c7f2ad256c300085dbf5069d0ae1ad0 | |
| ToppCell | saliva-Severe-critical_progression_d28-40-Myeloid-Granulocytic-Neutrophil-Neu_c6-FGF23|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.60e-03 | 180 | 19 | 2 | cf7d8bf9eee2dfab2c8a6780e296b05ad42041bf | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Hematopoietic-B_cells-Pro-B|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.60e-03 | 180 | 19 | 2 | e76ccbaba18ff27abbd71a41fd3574a5ac5c8fb4 | |
| ToppCell | 368C-Lymphocytic-ILC|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 2.60e-03 | 180 | 19 | 2 | ddba4dc3bbcfe4e4a22400be73bbc62d3ff27d3c | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid-granulocytopoietic_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.63e-03 | 181 | 19 | 2 | 566249e04dd491e6287ad2101b7b1ab11031ed8b | |
| ToppCell | TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Colon_Adenocarcinoma-5|TCGA-Colorectal / Sample_Type by Project: Shred V9 | 2.63e-03 | 181 | 19 | 2 | 8fcc9e77fee7c248df26b6c59b10e672242e2084 | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid-granulocytopoietic_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.63e-03 | 181 | 19 | 2 | db9528dc7cb0230e4c36cb27da69102c588c7ee9 | |
| ToppCell | Lymphoid-Lymphoid-T_cells_(cycle)|Lymphoid / shred on cell class and cell subclass (v4) | 2.63e-03 | 181 | 19 | 2 | b6b41cd5d43543fe7a093033dae52a789199db0e | |
| ToppCell | B_cell_maturation-immature_B_cell|World / Lineage and Cell class | 2.66e-03 | 182 | 19 | 2 | 2c7c51ebc4125d8a33454ffee0b143579ce5e451 | |
| ToppCell | droplet-Lung-LUNG-30m-Lymphocytic-Proliferating_NK|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.66e-03 | 182 | 19 | 2 | 0370b395ceb9d4d66f80cf60dd8c28ac60af5c7b | |
| ToppCell | facs-Marrow-B-cells-18m-Myeloid-granulocytopoietic_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.66e-03 | 182 | 19 | 2 | c075756cd4bb484ede1be2bcdb9eac60eab0573a | |
| ToppCell | facs-Marrow-B-cells-18m-Myeloid-granulocytopoietic_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.66e-03 | 182 | 19 | 2 | 9025178ede571e3808d4657ad4892152f336c9b4 | |
| ToppCell | LA-11._Adipocyte|World / Chamber and Cluster_Paper | 2.69e-03 | 183 | 19 | 2 | b177be283e1553fb1f69a346f1ba79ad00297fa2 | |
| ToppCell | Immune_cells-large_pre-B.|World / Lineage and Cell class | 2.69e-03 | 183 | 19 | 2 | 81b5ed6ed661d2d6a9b807fefd2f0d59bd4ea77e | |
| ToppCell | LA-11._Adipocyte|LA / Chamber and Cluster_Paper | 2.69e-03 | 183 | 19 | 2 | 3f9011976782fa8aa95cdd6f00f07a91094d411b | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_2|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 2.69e-03 | 183 | 19 | 2 | fef51dcf180e6d4e136362c7e140ec5ef372e6d0 | |
| ToppCell | 368C-Lymphocytic-CD4_T-cell-Treg_cell_2|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells) | 2.69e-03 | 183 | 19 | 2 | 310ad42b2b5d8ddd01d3a12db338f80ac1f5d08e | |
| ToppCell | 10x5'-bone_marrow-Lymphocytic_T_CD4/8-lo-Cycling_T|bone_marrow / Manually curated celltypes from each tissue | 2.69e-03 | 183 | 19 | 2 | a48a6313f2f144586951cece97ec31f6d72361df | |
| ToppCell | Hippocampus-Macroglia|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 2.72e-03 | 184 | 19 | 2 | a1d039ddf1e2a87b870f3ce6d139be56090349df | |
| ToppCell | normal_Lung-Fibroblasts-Myofibroblasts|normal_Lung / Location, Cell class and cell subclass | 2.72e-03 | 184 | 19 | 2 | 0b336489c10e8c3c957795dd845454f03404382b | |
| ToppCell | TCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Squamous_Cell_Carcinoma-3|TCGA-Lung / Sample_Type by Project: Shred V9 | 2.72e-03 | 184 | 19 | 2 | ea4ccebe2d54279fcc517e4f0bfa652b91a808bb | |
| ToppCell | Control-T_cells-Cycling_NK/T_cells|Control / group, cell type (main and fine annotations) | 2.75e-03 | 185 | 19 | 2 | 9766216b41ee62bbac4caa25cb98ec5627a24075 | |
| ToppCell | nucseq-Immune-Lymphocytic_T/NK-Lymphocytic_T/NK-Treg|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.75e-03 | 185 | 19 | 2 | a86a3a1a187a4d8d7762bc6d3dcb22c982178d22 | |
| ToppCell | facs-Skin-Anagen-3m-Epithelial-nan|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.78e-03 | 186 | 19 | 2 | 9a7932d0a208f3997216bd21a72913cc82b59fc9 | |
| ToppCell | droplet-Trachea-3m-Mesenchymal-fibroblast-fibroblast_of_trachea-tracheal_fibroblast_l1|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 2.78e-03 | 186 | 19 | 2 | 4e983de6d2515082f9e555f4f949cec84281c140 | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_T-T_NK-NK_T_cell|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 2.78e-03 | 186 | 19 | 2 | b099cb0902e9afb11218d70407d3cab212343c6d | |
| ToppCell | 5'-Adult-Appendix-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.78e-03 | 186 | 19 | 2 | 7582b5154d8e5a4434817b5ab77a10b789ea2288 | |
| ToppCell | 3'|World / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.78e-03 | 186 | 19 | 2 | e265aac37f33947ff6c83f23f8a2c63bbccd60af | |
| ToppCell | droplet-Bladder-nan|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.80e-03 | 187 | 19 | 2 | 663991a8afe652e92363b64bcbd68c14d0307f0e | |
| ToppCell | Smart-seq2-lymph_node_(Smart-seq2)-lymphocytic-T_lymphocytic-effector_CD4-positive,_alpha-beta_T_cell|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.80e-03 | 187 | 19 | 2 | e61c1755531469dd3850c9740474b5ad4e0499c1 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.80e-03 | 187 | 19 | 2 | d17352f769c3c66601b65d060626eecff41b0482 | |
| ToppCell | droplet-Marrow-nan-3m-Hematologic-megakaryocyte-erythroid_progenitor_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.80e-03 | 187 | 19 | 2 | 14c239af77116d28d511dea754b6150d20488080 | |
| Drug | Mephentermine hemisulfate [1212-72-2]; Up 200; 9.4uM; MCF7; HT_HG-U133A | 5.23e-07 | 200 | 19 | 5 | 3425_UP | |
| Drug | Clemizole hydrochloride [1163-36-6]; Down 200; 11uM; PC3; HT_HG-U133A | 1.76e-05 | 193 | 19 | 4 | 3672_DN | |
| Drug | SC 19220; Up 200; 10uM; PC3; HT_HG-U133A | 1.79e-05 | 194 | 19 | 4 | 7065_UP | |
| Drug | Felodipine [72509-76-3]; Down 200; 10.4uM; PC3; HT_HG-U133A | 1.79e-05 | 194 | 19 | 4 | 6695_DN | |
| Drug | azathioprine, USP; Up 200; 100uM; MCF7; HG-U133A | 1.83e-05 | 195 | 19 | 4 | 338_UP | |
| Drug | Ethisterone [434-03-7]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 1.83e-05 | 195 | 19 | 4 | 3864_DN | |
| Drug | estradiol, USP; Up 200; 0.01uM; ssMCF7; HG-U133A | 1.87e-05 | 196 | 19 | 4 | 414_UP | |
| Drug | Tiletamine hydrochloride; Up 200; 15.4uM; PC3; HT_HG-U133A | 1.90e-05 | 197 | 19 | 4 | 7311_UP | |
| Drug | Tetrahydroxy-1,4-quinone monohydrate [319-89-1]; Down 200; 21uM; MCF7; HT_HG-U133A | 1.90e-05 | 197 | 19 | 4 | 3338_DN | |
| Drug | Betonicine [515-25-3]; Down 200; 25.2uM; MCF7; HT_HG-U133A | 1.90e-05 | 197 | 19 | 4 | 6063_DN | |
| Drug | Chlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; MCF7; HT_HG-U133A | 1.90e-05 | 197 | 19 | 4 | 1541_DN | |
| Drug | Khellin [82-02-0]; Down 200; 15.4uM; MCF7; HT_HG-U133A | 1.90e-05 | 197 | 19 | 4 | 1504_DN | |
| Drug | Flunisolide [3385-03-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 1.94e-05 | 198 | 19 | 4 | 6023_DN | |
| Drug | Lomefloxacin hydrochloride [98079-52-8]; Down 200; 10.4uM; HL60; HT_HG-U133A | 1.94e-05 | 198 | 19 | 4 | 2348_DN | |
| Drug | Haloperidol [52-86-8]; Up 200; 10.6uM; PC3; HG-U133A | 1.94e-05 | 198 | 19 | 4 | 1955_UP | |
| Drug | Levopropoxyphene napsylate [5714-90-9]; Down 200; 7.4uM; MCF7; HT_HG-U133A | 1.98e-05 | 199 | 19 | 4 | 3543_DN | |
| Drug | Lomefloxacin hydrochloride [98079-52-8]; Down 200; 10.4uM; MCF7; HT_HG-U133A | 1.98e-05 | 199 | 19 | 4 | 2310_DN | |
| Drug | AC1L71LN | 1.57e-04 | 128 | 19 | 3 | CID000327966 | |
| Drug | UV-C | 3.21e-04 | 163 | 19 | 3 | CID005289542 | |
| Drug | 17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA | 3.95e-04 | 175 | 19 | 3 | 1006_UP | |
| Drug | 17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA | 4.15e-04 | 178 | 19 | 3 | 916_UP | |
| Drug | Adiphenine hydrochloride [50-42-0]; Down 200; 11.4uM; MCF7; HT_HG-U133A | 4.50e-04 | 183 | 19 | 3 | 1709_DN | |
| Drug | Nimodipine [66085-59-4]; Up 200; 9.6uM; HL60; HT_HG-U133A | 4.65e-04 | 185 | 19 | 3 | 3103_UP | |
| Drug | prochlorperazine dimaleate salt; Up 200; 10uM; MCF7; HT_HG-U133A | 4.80e-04 | 187 | 19 | 3 | 6975_UP | |
| Drug | Lovastatin [75330-75-5]; Up 200; 9.8uM; MCF7; HT_HG-U133A | 4.87e-04 | 188 | 19 | 3 | 2854_UP | |
| Drug | Antimycin A [1397-94-0]; Down 200; 7.2uM; HL60; HG-U133A | 4.87e-04 | 188 | 19 | 3 | 1414_DN | |
| Drug | Primaquine diphosphate [63-45-6]; Down 200; 8.8uM; MCF7; HT_HG-U133A | 4.87e-04 | 188 | 19 | 3 | 4845_DN | |
| Drug | Loperamide hydrochloride [34552-83-5]; Up 200; 7.8uM; PC3; HT_HG-U133A | 4.95e-04 | 189 | 19 | 3 | 4672_UP | |
| Drug | radicicol; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA | 4.95e-04 | 189 | 19 | 3 | 836_UP | |
| Drug | Ivermectin [70288-86-7]; Up 200; 4.6uM; MCF7; HT_HG-U133A | 4.95e-04 | 189 | 19 | 3 | 7206_UP | |
| Drug | F0447-0125; Up 200; 10uM; PC3; HT_HG-U133A | 5.02e-04 | 190 | 19 | 3 | 6429_UP | |
| Drug | AC1MQZ6I | 5.02e-04 | 190 | 19 | 3 | CID003509873 | |
| Drug | Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A | 5.10e-04 | 191 | 19 | 3 | 4279_DN | |
| Drug | 17-DMAG; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA | 5.10e-04 | 191 | 19 | 3 | 993_UP | |
| Drug | Drofenine hydrochloride [548-66-3]; Up 200; 11.4uM; MCF7; HT_HG-U133A | 5.10e-04 | 191 | 19 | 3 | 6776_UP | |
| Drug | Albendazole [54965-21-8]; Down 200; 15uM; MCF7; HT_HG-U133A | 5.18e-04 | 192 | 19 | 3 | 3164_DN | |
| Drug | Dipyridamole [58-32-2]; Down 200; 8uM; MCF7; HT_HG-U133A | 5.18e-04 | 192 | 19 | 3 | 1517_DN | |
| Drug | Sulfamethoxazole [723-46-6]; Down 200; 15.8uM; HL60; HT_HG-U133A | 5.18e-04 | 192 | 19 | 3 | 2335_DN | |
| Drug | Betamethasone [378-44-9]; Up 200; 10.2uM; PC3; HT_HG-U133A | 5.18e-04 | 192 | 19 | 3 | 6728_UP | |
| Drug | Chlorhexidine [55-56-1]; Up 200; 8uM; MCF7; HT_HG-U133A | 5.18e-04 | 192 | 19 | 3 | 1525_UP | |
| Drug | Ethynodiol diacetate [297-76-7]; Up 200; 10.4uM; PC3; HT_HG-U133A | 5.26e-04 | 193 | 19 | 3 | 6678_UP | |
| Drug | Naphazoline hydrochloride [550-99-2]; Down 200; 16.2uM; PC3; HT_HG-U133A | 5.26e-04 | 193 | 19 | 3 | 6604_DN | |
| Drug | Carisoprodol [78-44-4]; Up 200; 15.4uM; MCF7; HT_HG-U133A | 5.26e-04 | 193 | 19 | 3 | 3251_UP | |
| Drug | prochlorperazine dimaleate salt; Up 200; 10uM; MCF7; HG-U133A | 5.26e-04 | 193 | 19 | 3 | 455_UP | |
| Drug | Zidovudine, AZT [30516-87-1]; Up 200; 15uM; PC3; HT_HG-U133A | 5.26e-04 | 193 | 19 | 3 | 6733_UP | |
| Drug | Clorgyline hydrochloride [17780-75-5]; Up 200; 13uM; MCF7; HT_HG-U133A | 5.26e-04 | 193 | 19 | 3 | 5005_UP | |
| Drug | Butoconazole nitrate [32872-77-1]; Up 200; 8.4uM; MCF7; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 3288_UP | |
| Drug | Quercetine dihydrate [6151-25-3]; Down 200; 11.8uM; PC3; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 4264_DN | |
| Drug | CP-690334-01 [459212-38-5]; Up 200; 10uM; MCF7; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 3906_UP | |
| Drug | CP-645525-01 [287190-82-3]; Up 200; 10uM; PC3; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 7527_UP | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 2474_DN | |
| Drug | Tolazoline hydrochloride [59-97-2]; Down 200; 20.4uM; PC3; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 4262_DN | |
| Drug | Chlorthalidone [77-36-1]; Down 200; 11.8uM; HL60; HG-U133A | 5.34e-04 | 194 | 19 | 3 | 1581_DN | |
| Drug | Dapsone [80-08-0]; Up 200; 16.2uM; HL60; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 1868_UP | |
| Drug | Carteolol hydrochloride [51781-21-6]; Down 200; 12.2uM; MCF7; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 4176_DN | |
| Drug | Khellin [82-02-0]; Up 200; 15.4uM; MCF7; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 4987_UP | |
| Drug | Griseofulvin [126-07-8]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 5.34e-04 | 194 | 19 | 3 | 2293_DN | |
| Drug | Hexylcaine hydrochloride [532-76-3]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 6244_UP | |
| Drug | ST021200; Down 200; 10uM; PC3; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 7493_DN | |
| Drug | Antazoline hydrochloride [2508-72-7]; Down 200; 13.2uM; MCF7; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 3173_DN | |
| Drug | Indapamide [26807-65-8]; Down 200; 10.6uM; PC3; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 3778_DN | |
| Drug | Famprofazone [22881-35-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 3834_DN | |
| Drug | Cytisine (-) [485-35-8]; Down 200; 21uM; PC3; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 5739_DN | |
| Drug | Oxalamine citrate salt [1949-20-8]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 4969_UP | |
| Drug | Clomiphene citrate (Z,E) [50-41-9]; Up 200; 6.6uM; MCF7; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 2624_UP | |
| Drug | Lactobionic acid [96-82-2]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 3246_UP | |
| Drug | Metoprolol-(+,-) (+)-tartrate salt [56392-17-7]; Down 200; 5.8uM; PC3; HT_HG-U133A | 5.42e-04 | 195 | 19 | 3 | 4508_DN | |
| Drug | trichostatin A; Up 200; 0.1uM; ssMCF7; HG-U133A | 5.50e-04 | 196 | 19 | 3 | 413_UP | |
| Drug | Dehydrocholic acid [81-23-2]; Down 200; 9.6uM; HL60; HG-U133A | 5.50e-04 | 196 | 19 | 3 | 2023_DN | |
| Drug | Cinnarizine [298-57-7]; Down 200; 10.8uM; HL60; HG-U133A | 5.50e-04 | 196 | 19 | 3 | 1558_DN | |
| Drug | Amethopterin (R,S) [59-05-2]; Up 200; 8.8uM; MCF7; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 5000_UP | |
| Drug | Ethambutol dihydrochloride [1070-11-7]; Down 200; 14.4uM; MCF7; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 4120_DN | |
| Drug | Eucatropine hydrochloride [536-93-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 3416_UP | |
| Drug | Aminopurine, 6-benzyl [1214-39-7]; Down 200; 17.8uM; PC3; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 3726_DN | |
| Drug | LY 294002; Down 200; 10uM; HL60; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 2687_DN | |
| Drug | Hydroxyzine dihydrochloride [2192-20-3]; Down 200; 9uM; MCF7; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 1524_DN | |
| Drug | 1,1-dimethylbiguanide hydrochloride; Down 200; 10uM; MCF7; HG-U133A | 5.50e-04 | 196 | 19 | 3 | 2_DN | |
| Drug | Cefamandole sodium salt [30034-03-8]; Up 200; 8.2uM; MCF7; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 4718_UP | |
| Drug | Esculin Hydrate [531-75-9]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 5411_DN | |
| Drug | Sisomicin sulfate [53179-09-2]; Down 200; 2.8uM; HL60; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 2493_DN | |
| Drug | Glibenclamide [10238-21-8]; Up 200; 8uM; PC3; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 5849_UP | |
| Drug | Diphemanil methylsulfate [62-97-5]; Down 200; 10.2uM; MCF7; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 1494_DN | |
| Drug | Sulfisoxazole [127-69-5]; Down 200; 15uM; MCF7; HT_HG-U133A | 5.50e-04 | 196 | 19 | 3 | 5257_DN | |
| Drug | pentamidine isethionate salt; Down 200; 100uM; MCF7; HG-U133A | 5.58e-04 | 197 | 19 | 3 | 639_DN | |
| Drug | Droperidol [548-73-2]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 2645_UP | |
| Drug | Tetrahydroxy-1,4-quinone monohydrate [319-89-1]; Up 200; 21uM; PC3; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 4078_UP | |
| Drug | Furaltadone hydrochloride [3759-92-0]; Down 200; 11uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 3838_DN | |
| Drug | Trichlorfon [52-68-6]; Up 200; 15.6uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 1675_UP | |
| Drug | 0198306-0000 [212631-61-3]; Down 200; 10uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 7064_DN | |
| Drug | genistein; Down 200; 10uM; PC3; HG-U133A | 5.58e-04 | 197 | 19 | 3 | 703_DN | |
| Drug | Harmol hydrochloride monohydrate [40580-83-4]; Up 200; 15.8uM; HL60; HG-U133A | 5.58e-04 | 197 | 19 | 3 | 1750_UP | |
| Drug | Dubinidine [22964-77-8]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 6250_UP | |
| Drug | Heliotrine [303-33-3]; Down 200; 12.8uM; PC3; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 4277_DN | |
| Drug | Chlorogenic acid [327-97-9]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 4142_DN | |
| Drug | Myosmine [532-12-7]; Down 200; 27.4uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 6055_DN | |
| Drug | Moxonidine [75438-57-2]; Up 200; 16.6uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 7343_UP | |
| Drug | Dexamethasone acetate [1177-87-3]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 6271_UP | |
| Drug | Cinchonine [118-10-5]; Up 200; 13.6uM; PC3; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 3988_UP | |
| Drug | Proxyphylline [603-00-9]; Down 200; 16.8uM; PC3; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 7290_DN | |
| Drug | Sulfathiazole [72-14-0]; Down 200; 15.6uM; MCF7; HT_HG-U133A | 5.58e-04 | 197 | 19 | 3 | 1463_DN | |
| Disease | hepatocellular carcinoma (is_marker_for) | 7.66e-04 | 301 | 18 | 3 | DOID:684 (is_marker_for) | |
| Disease | stomach cancer (is_implicated_in) | 8.76e-04 | 72 | 18 | 2 | DOID:10534 (is_implicated_in) | |
| Disease | lung cancer (is_implicated_in) | 9.25e-04 | 74 | 18 | 2 | DOID:1324 (is_implicated_in) | |
| Disease | Awakening Epilepsy | 1.13e-03 | 82 | 18 | 2 | C0751111 | |
| Disease | Aura | 1.13e-03 | 82 | 18 | 2 | C0236018 | |
| Disease | Epilepsy, Cryptogenic | 1.13e-03 | 82 | 18 | 2 | C0086237 | |
| Disease | Epilepsy | 1.99e-03 | 109 | 18 | 2 | C0014544 | |
| Disease | colorectal cancer (is_implicated_in) | 2.44e-03 | 121 | 18 | 2 | DOID:9256 (is_implicated_in) | |
| Disease | Malignant neoplasm of breast | 3.55e-03 | 1074 | 18 | 4 | C0006142 | |
| Disease | prostate cancer (is_marker_for) | 4.02e-03 | 156 | 18 | 2 | DOID:10283 (is_marker_for) | |
| Disease | colorectal cancer (is_marker_for) | 4.07e-03 | 157 | 18 | 2 | DOID:9256 (is_marker_for) | |
| Disease | hepatocellular carcinoma (is_implicated_in) | 5.37e-03 | 181 | 18 | 2 | DOID:684 (is_implicated_in) | |
| Disease | Prostatic Neoplasms | 5.85e-03 | 616 | 18 | 3 | C0033578 | |
| Disease | Malignant neoplasm of prostate | 5.85e-03 | 616 | 18 | 3 | C0376358 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| QDDCNGFQDSDDFAD | 546 | Q6ULP2 | |
| DNSFDLNNGSDAEQE | 381 | Q9UIF9 | |
| DGNQVGANDADSDDE | 621 | Q9H1I8 | |
| SDTDEDNGNGEDFQS | 2741 | P49792 | |
| DNNENAGEDGDNDFS | 1441 | Q9Y4B6 | |
| DGANDCGSNEDESNQ | 906 | Q9NZR2 | |
| NPNQDDDDDEGFSFN | 526 | Q09161 | |
| YNGNDVDFQDASDDG | 471 | P35052 | |
| NALGQYNDDDDDDDG | 176 | Q15910 | |
| AASEDENGDDQGFQE | 126 | Q00839 | |
| GDNGEAFFVQETDND | 81 | Q14693 | |
| DAGVEDAADANNGAQ | 241 | O60337 | |
| YGENDENTDDKNNDG | 641 | O00461 | |
| DNTENDLNQGDDHGF | 21 | Q13418 | |
| FDNEDSELNGDYGEN | 126 | Q96PC5 | |
| DNQNDDSEEHDDGGY | 391 | Q9NUP7 | |
| EDAFDNNSDIAEDGG | 31 | Q9BZ95 | |
| NEDIDDDGHQNNQDN | 861 | P35442 | |
| NGNAENEENGEQEAD | 36 | P06454 |